Table 2.
Factors associated with disease control in the entire population (N = 243).
| Characteristic | Multivariable model with csRDIs * | Multivariable model with cmRDI † | ||||
|---|---|---|---|---|---|---|
| Adjusted OR | 95% CI adjusted OR | Adjusted p-value | Adjusted OR | 95% CI adjusted OR | Adjusted p-value | |
| Relative dose intensity | ||||||
| OR/10% | ||||||
| csRDI oxaliplatin | 1.01 | (0.71–1.43) | 0.97 | |||
| csRDI irinotecan | 1.09 | (0.83–1.43) | 0.55 | |||
| csRDI 5FU bolus | 0.98 | (0.83–1.15) | 0.80 | |||
| csRDI 5FU continuous infusion | 0.99 | (0.59–1.65) | 0.96 | |||
| cmRDI FOLFIRINOX | 1.06 | (0.86–1.31) | 0.58 | |||
| ECOG PS | 0.003 | 0.004 | ||||
| 1 | 0.29 | (0.13–0.65) | 0.29 | (0.13–0.65) | ||
| 0 | 1 (ref) | 1 (ref) | ||||
| Liver metastasis | 0.004 | 0.004 | ||||
| Yes | 0.35 | (0.16–0.72) | 0.35 | (0.17–0.72) | ||
| No | 1 (ref) | 1 (ref) | ||||
| Number of cycles before first reassessment ‡ | <0.0001 | <0.0001 | ||||
| OR/1 cycle | 2.23 | (1.46–3.39) | 2.27 | (1.50–3.42) | ||
| Center | 0.043 | 0.027 | ||||
| Center 1 | 1 (ref) | 1 (ref) | ||||
| Center 2 | 0.51 | (0.2–1.57) | 0.50 | (0.2–1.44) | ||
| Center 3 | 0.41 | (0.1–1.73) | 0.40 | (0.1–1.64) | ||
| Center 4 | 0.20 | (0.1–0.76) | 0.18 | (0.1–0.67) | ||
| Center 5 | 1.44 | (0.4–4.66) | 1.38 | (0.4–4.31) | ||
| Center 6 | 2.25 | (0.6–8.88) | 2.23 | (0.6–7.66) | ||
The multivariable model evaluating the effect of csRDI included the csRDI of the four component agents (oxaliplatin, irinotecan, 5FU bolus, and 5FU continuous infusion) as well as ECOG PS, liver metastasis, number of cycles before first assessment, and center.
The multivariable model evaluating the effect of cmRDI included cmRDI, ECOG PS, liver metastasis, and center.
The variable “number of cycles before first reassessment” was incorporated as a continuous variable into the model after checking the monotonicity of the association. Taking three cycles before reassessment as a reference, the ORs for 4, 5, and 6 cycles were 2.76, 2.98, and 10.33, respectively.
CI, confidence interval; cmRDI, cumulative multi-drug relative dose intensity; csRDI, cumulative single-agent relative dose intensity; ECOG, Eastern Cooperative Oncology Group; OR, odds ratio; PS, performance status; ref, reference.